Platelets are a remarkable mammalian adaptation that are required for human survival by
virtue of their ability to prevent and arrest bleeding. Ironically, however, in the past century …

Platelet G-protein–coupled receptors influence platelet function by mediating the response
to various agonists, including ADP, thromboxane A2, and thrombin. Blockade of the ADP …

Following vessel wall injury, platelets adhere to the exposed subendothelium, become
activated and release mediators such as TXA 2 and nucleotides stored at very high …

New drugs are introduced to the market every year and each represents a privileged
structure for its biological target. These new chemical entities (NCEs) provide insights into …

Platelet activation has been implicated in microvascular thrombosis and organ failure in
critically ill patients. In the first part the present paper summarises important data on the role …

In the search of a potential backup for clopidogrel, we have initiated a HTS campaign
designed to identify novel reversible P2Y12 antagonists. Starting from a hit with low …

Abstract P2Y 12 receptor (P2Y 12-R) is one of the major targets for drug inhibiting platelet
aggregation in the treatment/prevention of arterial thrombosis. However, the clinical use of …

Abstract Ticagrelor (Brilique™; Brilinta™), a cyclopentyl-triazolo-pyrimidine antiplatelet
agent, is the first oral antagonist of the P2Y 12 receptor to offer reversible receptor binding. It …

Introduction: P2Y12 inhibitors are a critical component of dual antiplatelet therapy (DAPT),
which is the superior strategy to prevent arterialthrombosis in patients with acute coronary …

Platelets play an important role both in normal hemostasis and in pathological thrombus
formation. Several large-scale clinical studies have proved that the inhibition of platelet …